Evidence map›Paper›PMID 21654680›Full record

ArticleBritish journal of cancer2011

How to minimise the effect of tumour cell content in detection of aberrant genetic markers in neuroblastoma.

M Piqueras, S Navarro, A Cañete, V Castel, R Noguera

Abstract read
In one paragraph

Article in British journal of cancer, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

M PiquerasDepartment of Pathology, Medical School, University of Valencia, Avda. Blasco Ibáñez, 17, 46010 Valencia, Spain.
S Navarro
A Cañete
V Castel
R Noguera

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundClinical heterogeneity reflects the complexity of genetic events associated with neuroblastoma (NB). To identify the status of all described genetic loci with possible prognostic interest, high-throughput approaches have been used, but only with tumour cell content >60%. In some tumours, necrotic, haemorrhagic and/or calcification areas influence the low amount of neuroblasts. We evaluated the effect of tumour cell content in the detection of relevant aberrant genetic markers (AGM) diagnosed by fluorescence in situ hybridisation (FISH) on tissue microarrays (TMA) in NB.

methodsTwo hundred and thirty-three MYCN non-amplified primary NB included in 12 TMAs were analysed.

resultsPresence of AGM reduced event-free survival (EFS) (P=0.004) as well as overall survival (OS) (P=0.004) of patients in the whole cohort. There were no differences in prognostic impact of presence of AGM according to tumour cell content.

conclusionWe propose the use of FISH to diagnose AGM of all NB samples having the above-mentioned areas to determine patient risk.

Indexed as

Genetic MarkersChromosome MappingFemaleGene AmplificationHumansInfantIn Situ Hybridization, FluorescenceMaleNeoplasm StagingNeuroblastomaN-Myc Proto-Oncogene ProteinNuclear ProteinsOncogene ProteinsPrognosisSurvival RateTissue Array AnalysisGenetic MarkersMYCN protein, humanN-Myc Proto-Oncogene ProteinNuclear ProteinsOncogene Proteins

Identifiers

PMID21654680
PMCPMC3137406

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.